Our proprietary platform technology enables for the development of infusible therapeutics that target harmful antibodies in autoimmune diseases, transplant rejection or drug neutralization of biotherapeutics. Ablevia’s selective antibody depletion compounds can be readily adapted to target undesired antibodies in rare conditions with unmet clinical needs. The company was founded in 2018 at the Vienna Biocenter Campus and focusses on preclinical research and development.
Ablevia is reaching out for cooperation programs with strong partners that need to address undesired antibodies in preclinical and clinical settings.
Our proprietary platform technology enables for the development of infusible therapeutics that target harmful antibodies in autoimmune diseases, transplant rejection or drug neutralization of biotherapeutics. Ablevia’s selective antibody depletion compounds can be readily adapted to target undesired antibodies in rare conditions with unmet clinical needs. The company was founded in 2018 at the Vienna Biocenter Campus and focusses on preclinical research and development.
Ablevia is reaching out for cooperation programs with strong partners that need to address undesired antibodies in preclinical and clinical settings.
Ablevia
biotech
We remove disease-causing and neutralizing antibodies
[(c) stock.adobe.com]
Ablevia biotech GmbH
Maria Jacobi Gasse 1, MQM 3.2
1030 Vienna
AUSTRIA
contact us
member of
funding
& partners
supported by BMWFW / aws & FFG
Initial private investments in combination with non-dilutive funding by federal institutions, supports technology setup and facilitates Ablevia's independence in seed phase. Ablevia has received funding from the Austrian Research Promotion Agency (FFG Early Stage program) and was awarded a Seedfinancing program by the Austrian promotional bank aws.
Austrian Research Promotion Agency
Location on Google Maps - here
(c) 2021 Ablevia biotech GmbH, Vienna Biocenter, Österreich
selective antibody removal therapeutics